|Day Low/High||3.47 / 3.70|
|52 Wk Low/High||1.90 / 7.45|
The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.
The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.
Small biotech stocks have a number of hurdles around FDA approval. Here is how to play that cycle.
Winning FDA approval isn't always a win.
The experiences of three biotechs show how drug approvals don't always translate into stock gains.
Hurricane Harvey was upgraded to a category 2 storm overnight and could be a category 3 before the day is over.
This sector is one of the few areas of the market where you'll find myriad compelling values.